This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biosense Webster Announces FDA Approval Of The THERMOCOOL® SF Catheter In The United States

Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the FDA approval of the new THERMOCOOL ® SF irrigated ablation catheter in the United States.

The THERMOCOOL ® SF NAV Catheter combines Biosense Webster’s latest irrigated ablation technology with the accurate visualization of the CARTO ®3 3D Mapping & Ablation System. The catheter was launched in Europe in October, 2010 and has received excellent feedback from electrophysiologists who have used the product.

The THERMOCOOL ® SF NAV Catheter is approved in the United States for treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation when used with CARTO ® Systems and Type 1 Atrial Flutter for patients 18 years and older.

Unlike competitive irrigated technologies, the innovative catheter design and breakthrough porous tip technology with Surround Flow technology of the THERMOCOOL ® SF Catheter allows for uniform cooling of the entire catheter tip, and efficient heat dissipation when ablating. This cutting edge innovation provides more effective cooling and allows half the volume load to the patient, when compared to the traditional THERMOCOOL ® Catheter.

“We are proud to offer electrophysiologists in the United States our latest irrigated ablation technology to help treat patients with cardiac arrhythmias,” said Shlomi Nachman, Worldwide President, Biosense Webster. “With the introduction of the THERMOCOOL ® SF Catheter, we reinforce our market leadership in the electrophysiology marketplace and our passion for excellence in knowledge and innovation.”

About AF and cardiac ablation

Atrial Fibrillation is the most prevalent arrhythmia, and is a leading cause of stroke among people 65 years and older. Worldwide, it is estimated that 20 million people have AF, yet only ~130,000 are treated with ablation every year. The public health implications of AF are a growing concern because those with AF are at an increased risk of morbidity and mortality as well as a reduced quality of life.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,960.76 -109.64 -0.61%
S&P 500 2,094.70 -19.79 -0.94%
NASDAQ 4,944.2040 -72.7250 -1.45%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs